FindMyKOL

Sean Adrean, MD

Enriched profile

Retina Specialist · Retina Consultants of Orange County

ORCID↗NPI↗
✓ Itemized profile
Region🇺🇸 Fullerton, CA · West · United StatesSpecialtyRetina SpecialistFocusRetinal Diseases and Treatments+4
Active KOLFindMyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Sean Adrean is Retina Specialist at Retina Consultants of Orange County. OpenAlex indexes 54 publications with 1,793 citations (h-index 13); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 4 Nov 2026

Overview

Updated 4 Nov 2026

Sean Adrean, MD, is Retina Specialist at Retina Consultants of Orange County. The public record shows 54 publications with 1,793 citations (h-index 13), centered on Retinal Diseases and Treatments, Retinal and Macular Surgery, Ocular Diseases and Behçet’s Syndrome. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 28 companies.

  • Top research focus: Retinal Diseases and Treatments
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 28 companies

Generated from the cited public record · current as of 4 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Diabetic Complications1 trialDiabetic Retinopathy / DME1 trialEdema1 trialMacular Edema1 trialMacular Degeneration (AMD)GlaucomaLupus (SLE)

Research focus

OpenAlex concept fingerprint
Retinal Diseases and TreatmentsRetinal and Macular SurgeryOcular Diseases and Behçet’s SyndromeOcular Infections and TreatmentsRetinopathy of Prematurity Studies

Drugs & molecules

across trials, industry payments and publications
Vabysmogeneric · FaricimabClinical trials—Industry payments61Publications3Syfovregeneric · PegcetacoplanClinical trials—Industry payments32Publications1Ozurdexgeneric · DexamethasoneClinical trials—Industry payments27Publications1Eyleageneric · AfliberceptClinical trials—Industry payments21Publications1EYLEA HDClinical trials—Industry payments29Publications—Susvimogeneric · RanibizumabClinical trials—Industry payments15Publications—Iluviengeneric · FluocinoloneClinical trials—Industry payments10Publications—Izervaygeneric · Avacincaptad pegolClinical trials—Industry payments9Publications—Durystageneric · BimatoprostClinical trials—Industry payments3Publications—Acthargeneric · CorticotropinClinical trials—Industry payments2Publications—Beovugeneric · BrolucizumabClinical trials—Industry payments2Publications—Tepezzageneric · TeprotumumabClinical trials—Industry payments2Publications—

Works with

trial sponsors and companies reporting payments
Genentech USA, Inc.Clinical trials—Industry payments64Apellis Pharmaceuticals, Inc.Clinical trials—Industry payments42Regeneron Healthcare Solutions, Inc.Clinical trials—Industry payments31Abbvie Inc.Clinical trials—Industry payments24Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments12Alcon Vision LLCClinical trials—Industry payments11Alimera Sciences, Inc.Clinical trials—Industry payments8Astellas Pharma US IncClinical trials—Industry payments6Coherus Biosciences Inc.Clinical trials—Industry payments5Astellas Pharma Global DevelopmentClinical trials—Industry payments4EyePoint Pharmaceuticals US, Inc.Clinical trials—Industry payments4Genentech, Inc.Clinical trials—Industry payments4Ocular Therapeutix, Inc.Clinical trials—Industry payments4ANI Pharmaceuticals, Inc.Clinical trials—Industry payments2Bausch & Lomb Americas Inc.Clinical trials—Industry payments2Biogen, Inc.Clinical trials—Industry payments2Horizon Therapeutics plcClinical trials—Industry payments2Novartis Pharmaceuticals CorporationClinical trials—Industry payments2Sight Sciences, Inc.Clinical trials—Industry payments2Aerie Pharmaceuticals, Inc.Clinical trials—Industry payments1Cardinal Health 110 LLCClinical trials—Industry payments1Dutch Ophthalmic, USAClinical trials—Industry payments1Harrow Eye, LLCClinical trials—Industry payments1Johnson & Johnson Surgical Vision, Inc.Clinical trials—Industry payments1Mallinckrodt Hospital Products Inc.Clinical trials—Industry payments1Retina Consultants of Orange CountyClinical trials1Industry payments—Sun Pharmaceutical Industries Inc.Clinical trials—Industry payments1Thea Pharma Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
54publications

Publications indexed by OpenAlex, matched via ORCID. 13 in PubMed. Counts exclude supporting files.

1,793citations

Citations across these publications.

13h-index

H-index from these publications. i10-index 14.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
28companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

An office address from a public listing. This research profile has no federal registry record to draw from.

Office address

301 W. Bastanchury Road Suite 285 Fullerton, CA 92835

From the cited public source.Collected 4 Nov 2026.View source ↗

Clinical trials

Updated 4 Nov 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 4 Nov 2026

28 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 61 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

All 13 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
    Article512 citations2023
    doi.org ↗
  2. 02
    Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
    Article504 citations2022
    doi.org ↗
  3. 03
    Faricimab Treat-and-Extend for Diabetic Macular Edema
    Article176 citations2023
    doi.org ↗
  4. 04
    Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration
    Article111 citations2023
    doi.org ↗
  5. 05
    Autologous Retinal Transplantation for Primary and Refractory Macular Holes and Macular Hole Retinal Detachments
    Article98 citations2020
    doi.org ↗
All 54 cited works: search, sort and filter.Explore →

Online presence

Updated 4 Nov 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/sean-adrean-1a988213

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/p/DdhjZuKkrf5

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗
  • Other

    ophthalmology360.com/retina/photon-trial-assesses-aflibercept-8-mg-for-diabetic-macular-edema

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ophthalmology360.com ↗
  • Other

    asrs.org/find-a-specialist/profile/2456/Sean-David-Adrean

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →asrs.org ↗
  • Other

    hcplive.com/view/sean-adrean-md-impact-baseline-va-aflibercept-8-mg-outcomes-dme

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →hcplive.com ↗
  • Other

    thedoctorschannel.com/view/impact-of-central-retinal-thickness-on-outcomes-in-dme

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thedoctorschannel.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 4 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    Loma Linda University

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinaconsultants-socal.com ↗
  • Degree in Chemistry

    University of California at San Diego (Magna Cum Laude)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →providence.org ↗
  • Diplomate

    The American Board of Ophthalmology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinaconsultants-socal.com ↗

Editorial & leadership roles

journal and society appointments
  • Fellow

    American Academy of Ophthalmology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinaconsultants-socal.com ↗
  • FASRS

    American Society of Retina Specialists

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asrs.org ↗
  • Editor for multiple journals in ophthalmology
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinaconsultants-socal.com ↗
  • Board member

    OCEP

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗
  • Program chair

    Orange County Society of Ophthalmology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.